The Use of High Bile-Binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations: A Novel Intervention for Children at Risk for Aspiration-Associated Complications (Aim 3)

Using a longitudinal cohort design, we will compare the impact of a high BA-binding blenderized diet compared to a low BA-binding blenderized diet and an amino acid-based formula, on gastrointestinal and pulmonary hospitalization and emergency room visit rates over six months.

开始日期2025-08-01

申办/合作机构

The Children's Hospital Corp.

NCT06652698

/ Not yet recruitingN/AIIT

Early Supplementation for Cow's Milk Allergy Prevention in Breastfed Infants in Poland (ESCAPE-PL): a Protocol for Randomised Controlled Trial

Cow's milk allergy (CMA) is a common food allergy in infants and young children that can have a significant impact on the individual and their family due to dietary restrictions, risk of nutritional deficiencies, social limitations, and decreased quality of life. It also represents a financial burden for families and healthcare resources.
There is an ongoing debate about the significance of early exposure to cow's milk proteins within hours or days after birth and its relationship to the risk of developing CMA later in life. Current recommendations for early introduction of cow's milk proteins in infants who cannot be breastfed vary and are inconsistent due to a lack of clear evidence. This knowledge gap underscores the need for further research to provide a definitive understanding of the relationship between early exposure to cow's milk proteins and the development of CMA, which will ultimately inform evidence-based prevention strategies to improve the health and well-being of affected individuals and their families.
This trial aims to investigate whether early supplementation with various nutritional interventions (cow's milk formula [CMF], amino acids formula [AAF], donor human milk [DHM], or high-pressure processed "pascalized" donor human milk [DHM-P]) could serve as an effective strategy for the primary prevention of CMA in breastfed neonates.
This study is an open-label randomized, controlled, head-to-head trial with four parallel arms and allocation 1:1:1:1.

开始日期2025-07-01

申办/合作机构

Warszawski Uniwersytet Medyczny

[+1]

100 项与复方氨基酸相关的临床结果

登录后查看更多信息

100 项与复方氨基酸相关的转化医学

登录后查看更多信息

100 项与复方氨基酸相关的专利（医药）

登录后查看更多信息

723

项与复方氨基酸相关的文献（医药）

2025-07-03·INTERNATIONAL JOURNAL OF PHYTOREMEDIATION

Effects of exogenous amino acids on yttrium uptake and accumulation in tomato ( Solanum lycopersicum )

Article

作者: Wei, Zhenggui ; Ren, Meiyu ; Naseer, Sidra ; Cui, Jing ; Wu, Junliang ; Sajid, Ali

This study investigated the impacts of exogenous amino acid supplementation on the uptake, translocation, and accumulation of yttrium (Y) in tomato plants (Solanum lycopersicum). To understand how amino acids enhance nutrient uptake and plant growth by using Hoagland nutrient solution. The results indicated that the combination of Y with glutamic acid (Y + Glu) significantly increased Y concentration in the leaves to 28.5 ± 1.42 µg g^-1, while the combination with histidine (Y + His) resulted in a markedly lower concentration of 2.7 ± 0.06 µg g^-1. Notably, glutamic acid proved to be particularly effective in enhancing Y accumulation in xylem sap. The control plants exhibited a higher xylem sap flow rate of 0.27 ± 0.008 g h^-1, which was significantly greater than those treated with amino acids (p < 0.05). Histidine levels were elevated in the Y + His treatment, reaching 194.78 ± 13.79 μmol L^-1, while tryptophan and aspartic acid showed their highest concentrations in their respective treatments at 109.92 ± 14.43 μmol L^-1 and 212.95 ± 13.65 μmol L^-1. These findings demonstrated that amino acid supplementation substantially enhanced the phytoextraction of Y in tomato plants, through the application of glutamic acid. Further exploration into the molecular mechanisms governing Y complexation and transport within plants through phytoremediation is needed.

2025-07-01·ACTA ANAESTHESIOLOGICA SCANDINAVICA

Effectiveness of amino acid supplementation in preventing acute kidney injury following cardiac surgery: A systematic review and meta‐analysis of randomized controlled trials

Review

作者: Salha, Issa ; Quirós, Melissa Chacón ; Andrabi, Suhaib ; Gallo Ruelas, Mariano ; Righetto, Bruno Branco ; Majeed, Mir Wajid ; Lopes, Lucca Moreira ; Finnegan, Emma ; Abujaber, Samer ; Tomo, Assaina Tatiana Jaquissone ; Delgado, Daniel ; Ahmad, Raheel

Abstract:

Introduction:

Acute kidney injury (AKI) is a frequent complication of cardiac surgery, contributing to increased morbidity, longer hospital stays, and higher mortality. Evidence suggests amino acid (AA) supplementation may enhance renal blood flow and glomerular filtration rate (GFR), potentially reducing AKI risk; however, findings remain inconclusive. This study evaluated the efficacy of perioperative AA supplementation in preventing AKI and related complications post‐cardiac surgery.

Methods:

PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing AA supplementation versus standard care in preventing cardiac surgery‐associated AKI. Main outcomes included AKI incidence (defined by the Kidney Disease Improving Global Outcomes (KDIGO) criteria), 30‐day mortality, and renal replacement therapy (RRT) requirement. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Statistical significance was set at p < 0.05. The certainty of the evidence (CoE) was assessed using the GRADE approach.

Results:

Six RCTs involving 4501 cardiac surgery patients were included. AA mixture interventions significantly reduced the risk of AKI stage 1 (RR: 0.56; 95% CI: 0.77–0.96; p = .009; CoE: Moderate) and Stage 3 (RR: 0.53; 95% CI: 0.34–0.83; p = .005; CoE: Moderate), but not stage 2 (RR: 1.24; 95% CI: 0.60–2.55; p = .568; CoE: Low). Preliminary findings from glutamic acid and glutamine (single AA interventions) showed potential benefits in reducing AKI incidence (CoE: Very low) and improving surrogate biomarkers, respectively. No significant effects were observed on mortality or RRT incidence for any intervention.

Conclusion:

AA mixtures likely reduce AKI incidence following cardiac surgery but show limited effects on mortality and RRT. Further trials are needed to confirm the benefits of glutamic acid and glutamine supplementation.

Editorial Comment:

Use of amino acid supplementation for the prevention of acute kidney injury after cardiac surgery may be effective, but more trial data and confidence in a beneficial effect is needed for this to be implemented in everyday clinical practice.

2025-06-01·Food Science & Nutrition

The Essentiality of Amino Acids in Healthiness and Disease State: Type II Diabetes as a Case Study.

Review

作者: Erukainure, Ochuko Lucky ; Zimbili Msomi, Nontokozo ; Fayomi, Samuel Idowu

A healthy life depends on the availability and the synthesis of amino acids as they are building blocks of proteins and regulators of principal physiological processes in organisms. Contemporary investigations have elucidated amino acids' roles in biological processes, emphasizing their contributions to preventing and treating metabolic disorders. Their structural architecture and nutritional importance elucidate their diverse biological roles, including muscle protein synthesis, immune support, neurological functions, and energy metabolism. Type 2 diabetes mellitus (T2DM), a prevalent metabolic disorder marked by insulin resistance and hyperglycemia, exemplifies a pertinent case for examining the relevance of amino acids in pathological conditions. The alteration of the amino acid profile, particularly high levels of leucine, isoleucine, and valine, is connected with insulin resistance and oxidative stress, which contribute to the progression of T2DM. In contrast, the potential therapeutic benefit of branched chain amino acid (BCAA) has earlier been reported to influence insulin signaling pathways, promote glucose uptake, and decrease inflammatory responses. However, the dosage and combination of amino acid intake through dietary interventions and supplementation may offer promising benefits to improve the management of T2DM effectively. This review investigates the functions of amino acids in normal physiological states, their potential as a diagnostic biomarker, the probable risk of deficiency, and the therapeutic ability for managing and preventing T2DM. Conversely, there is a need to intensively investigate the controversial dual role of BCAA in T2DM, the mechanism of amino acid actions in insulin resistance, the effect of a combination of amino acids, and the dosage limit in diabetic conditions.

253

项与复方氨基酸相关的新闻（医药）

2025-06-18

·米内网

科伦药业厉害了！拿下35个重磅品种，26款1类新药、74个新品出击，198个过评品种霸屏

精彩内容近段时间，科伦药业产品管线进展频频：1类新药注射用SKB315新适应症获批临床、注射用头孢唑林钠/氯化钠注射液国内第2家获批等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，2024年研发投入21.71亿元（+11.2%），目前有42款新药（26款1类新药）处于申报临床及以上阶段；仿制药方面，累计有198个品种过评（50余个首家/独家），74个新品瞄准160亿市场。拿下35个品种！198个过评品种霸屏近日，科伦药业2款3类仿制药获批生产并视同过评，为注射用头孢唑林钠/氯化钠注射液、注射用青霉素钠，均属于全身用抗感染药物。其中，注射用头孢唑林钠/氯化钠注射液国内第2家获批，同时也是公司粉液双室袋平台第11个获批的产品。今年以来，科伦药业（含子公司及联营公司，下同）产品管线持续推进。在新注册分类品种审评方面，科伦药业有35个品种获批生产并视同过评，领跑国内其他药企。2025年以来科伦药业获批上市的仿制药来源：米内网中国申报进度（MED）数据库35个品种中，有多个品种为国内首批上市，其中芦曲泊帕片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液等为国内首仿+首家过评，阿帕他胺片、枸橼酸钠血滤置换液、注射用头孢他啶/氯化钠注射液等为国产第2家获批，复方氨基酸注射液(18AA-Ⅸ)、他克莫司缓释胶囊、昂丹司琼口溶膜、复方电解质醋酸钠注射液等为国产第3家获批等。截至目前，科伦药业已有198个品种通过/视同通过一致性评价，在过评品种数TOP10集团中排位第二。其中，50余个品种为国内首家过评，包括芦曲泊帕片、氢溴酸替格列汀片、琥珀酸曲格列汀片、泊沙康唑口服混悬液、注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液等18个独家过评品种。在国家开展的九批十轮化药集采中，科伦药业分别有1个、5个、4个、4个、11个、11个、7个、4个、12个品种成功中选，合计59个品种。集采常态化推进背景下，科伦药业恰逢产品线密集收获期，并积极参与集采，目前已成为集采头部供应商之一。在第十一批集采中，预计科伦药业将仍旧为“主力军”，目前已有近40个品种达到入围门槛，注射剂占“半壁江山”。其中，有10余个为2025年后新获批品种，包括罗沙司他胶囊、注射用头孢他啶阿维巴坦钠(4:1)等临床畅销品种。26款1类新药出击，猛攻2300亿市场今年以来，科伦药业国内新药研发进展不断：生物类似药西妥昔单抗注射液获批上市，为国产首家；PD-L1单抗塔戈利单抗注射液、TROP2 ADC注射用芦康沙妥珠单抗获批新适应症；1类新药注射用SKB445、SKB107注射液，以及2.2类改良型新药KLA480注射液、注射用KLA578-1、KLA514-2片、A140注射液等均首次获批临床。国际化方面，新型ADC药物SKB518在美获批临床，用于治疗晚期实体瘤，该药已在国内开展II期临床试验；以不超过9.7亿美元的首付款和里程碑付款，将TSLP单抗SKB378/HBM93781在全球范围内（不包括大中华区以及部分东南亚及西亚国家）的研发、生产和商业化的独家授权给Windward Bio等。近年来，科伦药业坚持“三发驱动，创新增长”的发展战略，不断加大研发投入支持创新发展。2023年公司研发投入19.5亿元，同比增长7.59%；2024年进一步增长至21.71亿元，同比增长11.2%。近年来科伦药业研发投入情况（单位：亿元）来源：公司公告，米内网整理目前科伦药业有42款新药在国内处于申报临床及以上阶段，涉及26款1类新药、15款2类改良型新药、1款生物类似药，聚焦肿瘤、精神神经、心血管、肝病、呼吸等疾病领域，其中抗肿瘤药独占“半壁江山”。米内网数据显示，2024年中国三大终端六大市场抗肿瘤和免疫调节剂（化学药+生物药）销售额超过2300亿元。科伦药业国内在研新药来源：米内网综合数据库42款新药中，1类新药注射用博度曲妥珠单抗、制剂改良型新药布瑞哌唑口溶膜已申报NDA，上市可期。博度曲妥珠单抗为靶向HER2的ADC药物，全球已获批上市的同靶点同类型药物中，罗氏的恩美曲妥珠单抗、第一药品/阿斯利康的德曲妥珠单抗2024年全球销售额分别达19.98亿瑞士法郎、5.45亿美元。口溶膜制剂方面，昂丹司琼口溶膜已顺利获批，布瑞哌唑口溶膜、枸橼酸西地那非口溶膜2款产品报产在审，盐酸达泊西汀口溶膜、盐酸鲁拉西酮口溶膜等获批临床，提升了公司复杂制剂领域产线价值。在研1类新药中，ADC药物是科伦药业重点布局的药物形式之一，目前已有芦康沙妥珠单抗（TROP2 ADC）1款新药获批上市，此外还有9款ADC药物处于获批临床及以上阶段，其中新型双抗ADC药物SKB571，以及SKB518、MK-6204、SKB445等具有潜在FIC靶点的新型ADC药物等均处于I期临床。目前全球已有10多款ADC药物获批上市，2024年全球销售额合计约130亿美元。74个新品瞄准160亿市场！29个品种抢首仿仿制药申报方面，目前科伦药业还有74个新注册分类品种在审（不含已有批文、主动撤回品种），形成了梯度丰富的研发管线，主要集中在血液和造血系统药物（16个）、神经系统药物（15个）、全身用抗感染药物（8个）、消化系统及代谢药（7个）等。74个品种2024年在中国三大终端六大市场的销售额合计超过160亿元。其中，低钙腹膜透析液(乳酸盐-G1.5%)、艾拉莫德片均超过10亿元，低钙腹膜透析液(乳酸盐-G2.5%)、丙戊酸钠缓释片(Ⅰ)均超过9亿元，双氯芬酸二乙胺乳胶剂、磷酸芦可替尼片均超过8亿元。29个品种暂无首仿（含剂型首仿）获批上市，包括注射用头孢噻肟钠/氯化钠注射液、注射用盐酸头孢替安/氯化钠注射液、雌二醇地屈孕酮片、佩玛贝特片、苯磺酸氨氯地平口服溶液、甲磺酸沙非胺片、苹果酸奈诺沙星氯化钠注射液、注射用头孢唑肟钠/氯化钠注射液、右美沙芬安非他酮缓释片、注射用阿立哌唑、枸橼酸西地那非口溶膜、布瑞哌唑片、罗替高汀贴片、奈妥匹坦帕洛诺司琼胶囊、西尼莫德片、奥贝胆酸片等。科伦药业新分类申报在审且暂无首仿获批的品种来源：米内网中国申报进度（MED）数据库此外，注射用头孢哌酮钠舒巴坦钠氯化钠注射液、伊布替尼片、双氯芬酸钠贴片、瑞舒伐他汀依折麦布片(Ⅰ)、屈螺酮炔雌醇片、磷酸芦可替尼片、结构脂肪乳注射液(C6-24)、腹膜透析液(碳酸氢盐-G4.25%)、复方聚乙二醇电解质散(Ⅱ)、恩他卡朋双多巴片(Ⅱ)、布立西坦片、吡仑帕奈口服混悬液、10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)注射液等品种获批国产企业数均只有1家。资料来源：米内网数据库、公司公告等注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至6月16日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

一致性评价上市批准生物类似药

2025-06-16

·药物分子设计

小分子融合标签N11提升大肠杆菌重组蛋白可溶性表达

大肠杆菌因其低成本和完善的遗传操作体系，被广泛用作重组蛋白生产的底盘菌。然而，重组蛋白的可溶性表达仍是一个挑战。传统的大分子融合标签虽然能增强溶解度，但其较大的体积可能干扰目标蛋白的折叠与功能，且往往需要额外的酶切步骤，增加了生产成本。因此，开发小分子可溶性标签具有重要的应用价值。近日，来自新加坡科技研究局的Fong Tian Wong在Microbial Cell Factories发表了Further characterization and engineering of an 11-amino acid motif for enhancing recombinant soluble protein expression的文章。该研究主要针对大肠杆菌表达系统中重组蛋白可溶性低的问题，开发并优化了一种小分子融合标签NT11。作者设计了一种由11个氨基酸组成的小分子蛋白作为N-末端的标签，然后作者将从1-11位的氨基酸按顺序替换为丙氨酸，构成了从N11-A1到N11-A11共11个突变体。随后，作者使用常见的报道蛋白eGFP和在大肠杆菌中微溶的叶堆肥角质酶（Leaf Compost Cutinase, LCC-ICCG）、PET降解酶(FAST PETase, )为例测试N11溶解标签的作用效果，结果证明N11-A1在产量和溶解性的促进方面效果最好。随后通过基因检索，作者发现与N11序列类似的序列在天然蛋白中广泛存在，且既有位于N端，也有位于C端。因此，接下来作者以溶解效果较差的LCC-ICCG和甜味蛋白Brazzein为例，发现在N端和C端添加N11序列都可提高重组蛋白的产量，且不影响蛋白本身的折叠。最后，作者选取了成纤维细胞生长因子2（fibroblast growth factor 2，FGF2)和人表皮生长因子（human epidermal growth factor，hEGF）为例，通常哺乳动物的细胞在大肠杆菌中的可溶性并不高，为此作者使用N11和N11-A1分别在两种蛋白的N端和C端以及两侧构建了不同的构建体。结果相较于无标签组，带有N11标签的两种蛋白产量总体有明显提升，其中对于GF2，无论是 N 端、C 端或双标签 NT11，均能提升可溶性蛋白比例，说明标签能有效增强其溶解性。而hEGF只有C端携带标签产量才有明显提升，N端效果不明显，而两端甚至降低产量。因此，对于不同的蛋白表达，使用不同的融合策略更佳。总之，NT11作为一种高效、灵活的小分子融合标签，能在不损害目标蛋白功能的前提下显著提升其可溶性表达效率，为简化重组蛋白生产工艺、提高产量提供了一种极具潜力的解决方案。（梁尹摘译）

临床研究临床终止临床结果

2025-06-15

·米内网

【瞩目】输液龙头太猛了！科伦药业2款注射剂同日获批

精彩内容近日，国家药监局官网显示，科伦药业（含子公司）2款3类仿制药获批生产并视同过评，其中注射用头孢唑林钠/氯化钠注射液国内第2家获批，同时也是公司粉液双室袋平台第11个获批的产品；注射用青霉素钠2024年在中国公立医疗机构终端的销售额超过7亿元。注射用头孢唑林钠/氯化钠注射液是科伦药业粉液双室袋平台第11个获批的产品。此前，公司获批的粉液双室袋产品中，注射用比阿培南/氯化钠注射液、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用美罗培南/氯化钠注射液、注射用头孢他啶阿维巴坦钠/氯化钠注射液、注射用头孢西丁钠/葡萄糖注射液、注射用头孢曲松钠/氯化钠注射液、注射用头孢他啶/5%葡萄糖注射液等均为国内首家获批。科伦药业已获批的粉液双室袋产品来源：米内网中国上市药品（MID）数据库注射用青霉素钠为β-内酰胺类抗菌药，适用于敏感细菌所致各种感染，如脓肿、菌血症、肺炎和心内膜炎等。米内网数据显示，2023年中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院（简称中国公立医疗机构）终端注射用青霉素钠销售额超过9亿元，2024年有所回落。近年来中国公立医疗机构终端注射用青霉素钠销售情况（单位：万元）来源：米内网中国公立医疗机构药品终端竞争格局自2012年转型至今，科伦药业已成功实现了从单纯大输液到全面、综合、内涵发展的蜕变。今年以来，科伦药业（含子公司及联营公司）产品线收获颇丰（含非首次获批）。新药方面，注射用芦康沙妥珠单抗、塔戈利单抗注射液2款1类新药，以及西妥昔单抗注射液1款生物类似药获批上市；仿制药方面，35个品种获批生产并视同过评，其中注射剂占比超过57%，集中在血液和造血系统药物、消化系统及代谢药、全身用抗感染药物等治疗领域。35个仿制药中，有多个为国内首批获批，其中芦曲泊帕片、注射用亚胺培南西司他丁钠/氯化钠注射液、注射用比阿培南/氯化钠注射液等为国内首仿+首家过评，阿帕他胺片、枸橼酸钠血滤置换液、注射用头孢他啶/氯化钠注射液等为国产第2家获批，复方氨基酸注射液(18AA-Ⅸ)、他克莫司缓释胶囊、昂丹司琼口溶膜、复方电解质醋酸钠注射液等为国产第3家获批等。来源：米内网数据库、国家药监局官网等注：米内网《中国公立医疗机构药品终端竞争格局》，统计范围是：中国城市公立医院、县级公立医院、城市社区中心以及乡镇卫生院，不含民营医院、私人诊所、村卫生室；上述销售额以产品在终端的平均零售价计算。数据统计截至6月13日，如有疏漏，欢迎指正！免责声明：本文仅作医药信息传播分享，并不构成投资或决策建议。本文为原创稿件，转载文章或引用数据请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092【分享、点赞、在看】点一点不失联哦

上市批准生物类似药

100 项与复方氨基酸相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
极低出生体重婴儿	美国	B. Braun Medical, Inc.	1984-07-20
肝性脑病	美国	B. Braun Medical, Inc.	1982-08-03
尿毒症	美国	B. Braun Medical, Inc.	1978-02-24
营养紊乱	美国	B. Braun Medical, Inc.	1971-09-24
营养不良	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed \| Anesthesiology	N/A	慢性肾病 estimated glomerular filtration rate	812	Amino Acid Infusion	鏇糧顧積構顧醖淵鏇襯(簾顧製願繭淵餘鹹夢淵) = 夢鑰餘窪衊選範壓願膚構製齋淵觸膚製選膚襯 (餘糧衊艱鏇蓋鏇選襯鏇 ) 更多	积极	2025-05-01
				Amino Acid Infusion (Placebo)	鏇糧顧積構顧醖淵鏇襯(簾顧製願繭淵餘鹹夢淵) = 獵廠醖獵製襯簾範窪糧構製齋淵觸膚製選膚襯 (餘糧衊艱鏇蓋鏇選襯鏇 ) 更多
AAAAI2024	N/A	-	-	Amino Acid-Based Formula with An Alternative Carbohydrate (Standard AAF)	願簾構壓齋鑰構觸積壓(鹽膚鬱鬱壓簾艱鹽鏇網) = 衊憲遞鏇艱齋觸壓淵鏇鏇顧襯鬱餘鹽窪廠醖鑰 (鏇齋衊壓獵構製築構蓋 ) 更多	-	2024-02-23
				Amino Acid-Based Formula with An Alternative Carbohydrate (Alternative AAF)	願簾構壓齋鑰構觸積壓(鹽膚鬱鬱壓簾艱鹽鏇網) = 窪顧蓋憲簾構繭構膚糧鏇顧襯鬱餘鹽窪廠醖鑰 (鏇齋衊壓獵構製築構蓋 ) 更多
NCT03273712 (CTgov)	临床2期	脑膜瘤 \| 神经母细胞瘤 \| 髓母细胞瘤 ... 更多	39	68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan+Amino Acids	鏇艱鏇製憲遞襯衊襯蓋 = 範鑰網壓壓製鹹糧齋艱醖繭蓋獵淵夢餘鹹積製 (鏇觸蓋鏇顧壓憲鬱鬱窪, 艱顧鑰觸憲襯鬱鑰鏇齋 ~ 構獵襯製選鏇鹹餘範衊) 更多	-	2023-02-09
ATS2022	N/A	-	-	Amino Acids (VS009-2)	繭選憲鏇顧獵膚網醖鑰(鹽遞壓衊遞壓襯夢廠蓋) = 簾築壓鑰壓觸壓鑰艱壓製繭選網夢壓積醖襯夢 (窪膚憲廠顧製範鏇築糧, 0.08) 更多	-	2022-05-15
				Amino Acids (VX445/661/770)	繭選憲鏇顧獵膚網醖鑰(鹽遞壓衊遞壓襯夢廠蓋) = 窪壓糧製鏇網鹽夢選顧製繭選網夢壓積醖襯夢 (窪膚憲廠顧製範鏇築糧, 0.02) 更多
SNMMI2019	N/A	-	18	Commercial Amino Acid Infusion	糧餘壓鹽餘顧顧築憲願(簾淵網糧顧遞淵衊鏇夢) = 鹽壓糧範網顧壓窪艱顧膚壓憲積網衊構簾鹹齋 (積膚願餘顧鏇鬱遞衊蓋 ) 更多	积极	2019-05-21
				Compounded Amino Acid Infusion	鏇構遞網顧顧鹽製齋鏇(餘艱齋繭鹹衊鬱築鬱製) = 壓廠壓願觸艱醖觸鑰糧壓鑰膚構淵鹽餘蓋衊選 (窪鬱製衊夢窪繭遞窪衊 ) 更多
NCT01860573 (CTgov)	N/A	早产	168	Amino acids (Standard Amino Acids)	夢鹽範範齋醖糧鏇鹹蓋 = 簾鹹衊夢顧選繭鏇網餘築鑰選鏇鑰廠艱膚餘淵 (蓋鏇淵願壓遞蓋鹽遞鏇, 選網齋艱憲製餘餘憲遞 ~ 鑰廠選繭衊鏇餘願糧衊) 更多	-	2017-04-10
				Amino acids (High Amino Acids)	夢鹽範範齋醖糧鏇鹹蓋 = 築繭醖夢衊積鏇壓襯窪築鑰選鏇鑰廠艱膚餘淵 (蓋鏇淵願壓遞蓋鹽遞鏇, 餘廠鏇襯膚鹹簾夢顧顧 ~ 鬱顧積壓齋蓋夢醖遞憲) 更多
P079 (ECCO2013)	N/A	结肠炎	-	mixture of amino acids (Amino acids mixture (Thr, Met, Glu))	願顧繭壓鹹範糧觸鬱製(膚積鏇壓獵餘積廠繭遞) = 構艱淵艱鬱繭糧獵鬱襯艱衊廠範簾窪獵膚鹽蓋 (選鬱願網築鑰餘餘艱觸, 1.7%)	积极	2013-02-01
				mixture of amino acids (Alanine)	願顧繭壓鹹範糧觸鬱製(膚積鏇壓獵餘積廠繭遞) = 構艱壓鏇窪簾築簾鹽築艱衊廠範簾窪獵膚鹽蓋 (選鬱願網築鑰餘餘艱觸, 1.2%)